BioSpace News Archive

Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced the grant to two employees of non-statutory stock options for the purchase of up to an aggregate of 2,000 shares of Yumanity’s common stock.

Celularity Inc., a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, announced financial results for the third quarter ended September 30, 2021, and provided a corporate update.

ThermoGenesis Holdings, Inc., a market leader in automated cell processing tools and services in the cell and gene therapy field, reported financial and operating results for the third quarter ended September 30, 2021 and provided a corporate strategic update.

Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‛cytokine storm’ with its lead drug candidate, lenzilumab, today provided a corporate and regulatory update and reported financial results for the third quarter and nine months ended September 30, 2021.

Regeneron Pharmaceuticals, Inc. announced that its Board of Directors authorized a share repurchase program of up to $3 billion of the Company’s outstanding common stock.

Based in Fort Worth, Texas, Sanara MedTech Inc., a provider of surgical and chronic wound care products dedicated to improving patient outcomes, announced its strategic, operational and financial results for the quarter ended September 30, 2021.

Nyxoah SA announced that Olivier Taelman, Chief Executive Officer, will participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference on from November 22 to December 2, 2021.

Phathom Pharmaceuticals, Inc., a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced that members of its management team will participate at two upcoming virtual investor conferences.

China Pharma Holdings, Inc., an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, announced the financial results for the quarter ended September 30, 2021.

Senti Bio, a leading gene circuit company, today announced results from SENTI-401, one of its preclinical stage oncology programs, that aims to more precisely target tumors while sparing healthy cells.